 Tonix Pharmaceuticals Holding Corp NASDAQ: TNXP has announced the poster presentation of previously reported results from its Phase 3 RELIEF trial evaluating the TNX-102 SL tablet for the management of fibromyalgia. Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory, and mood issues. 